Since our data indicated that benefit of inhibiting IGF1/IGF1R pathway might be limited to MP subtype gastric cancer, possible reasons for current failure might be due to the lack of use of patient enrichment by biomarkers in the trials. The gene discussed is IGF1R; the disease is gastric cancer.